Further studies from Izumi and colleagues demonstrated that FABP4 treatment promoted serum-induced prostate cancer cell invasion in vitro and treatment with FABP4 inhibitor in mice reduced lung metastasis of prostate cancer cells [31]. Here, FABP4 is linked to prostate carcinoma.